NCT01260675已完成不适用
A Study to Assess the Pharmacokinetic Profile of an Investigational Formulation of Buprenorphine HCl/Naloxone HCl 8mg/2mg Capsules Relative to the Pharmacokinetic Profile of Suboxone® (Buprenorphine HCl/Naloxone HCl 8mg/2mg Sublingual Tablets).
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- pharmacokinetic profile of NanoBUP Capsules relative to Suboxone
研究概览
简要总结
Phase 1 study to determine the pharmacokinetic profile of NanoBUP Capsules to Suboxone.
详细描述
The pharmacokinetics of an orally administered investigational buprenorphine hydrochloride/naloxone hydrochloride 2 mg/0.5 mg capsule formulation will be studied. This is a single-dose, two period, two treatment, crossover comparative bioavailability study under fasting conditions.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Other
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subject must be a male or non-pregnant, non-breastfeeding female.
- •Subject must be between 18 and 55 years of age (inclusive).
- •Subject's Body Mass Index (BMI) must be between 18 and 30 kg/m2 (inclusive), and subject must weigh a minimum of 50 kg (110 lbs).
- •Female subjects - not surgically sterile for at least 6 months or at least 2 years postmenopausal - must agree to utilize one of the following forms of contraception, if sexually active with a male partner, from screening through completion of the study. Approved forms of contraception are abstinence, hormonal (oral, implant, transdermal, vaginal, or injection) in use at least 3 consecutive months prior to the first dose of study medication, double barrier (condom with spermicide; diaphragm with spermicide), intrauterine device (IUD), or vasectomized partner (6 months minimum since vasectomy).
- •Subject must voluntarily consent to participate in this study and provide their written informed consent prior to start of any study-specific procedures.
- •Subject is willing and able to remain in the study unit for the entire duration of the confinement period and return for any outpatient visits
排除标准
- •History or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, metabolic, dermatologic, neurologic, oncologic, or psychiatric disease or any other condition that, in the opinion of the Investigator, would jeopardize the safety of the subject or the validity of the study results.
- •A clinically significant abnormal finding on the physical exam, medical history, ECG, or clinical laboratory results at screening.
- •History or presence of allergic or adverse response to buprenorphine, naloxone, naltrexone, opioids, or any comparable or similar products.
- •Been on a significantly abnormal diet during the 4 weeks preceding the first dose of study medication.
- •Donated blood or plasma within 30 days prior to the first dose of study medication.
- •Participated in another clinical trial within 30 days prior to the first dose of study medication.
- •Used any over-the-counter (OTC) medication, including nutritional supplements, within 7 days prior to the first dose of study medication.
- •Used any prescription medication, except hormonal contraceptive or hormonal replacement therapy, within 14 days prior to the first dose of study medication.
- •Has been treated with any known enzyme altering drugs, such as barbiturates, phenothiazines, cimetidine, carbamazepine, etc., within 30 days prior to the first dose of study medication.
- •Smoked or used tobacco products within 60 days prior to the first dose of study medication.
- •History of substance abuse or dependence (including alcohol, opioids, or intravenous drug abuse)
- •Is a female with a positive pregnancy test result.
- •A positive urine screen for drugs of abuse (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, opiates).
- •A positive urine alcohol test at screening or a positive ethanol breath test at check-in for the study period or has consumed alcohol within 48 hours prior to screening or check-in for the study period.
- •Had a positive test for, or has been treated for hepatitis B, hepatitis C, or HIV.
研究组 & 干预措施
NanoBUP Capsules
Investigational Formulation of Buprenorphine HCl/Naloxone HCl 8 mg/2 mg oral capsules
干预措施: Buprenorphine HCl/Naloxone HCl (Drug)
Suboxone Sublingual Tablets
Buprenorphine HCl/Naloxone HCl 8 mg/2 mg sublingual tablets
干预措施: Buprenorphine HCl/Naloxone HCl (Drug)
结局指标
主要结局
pharmacokinetic profile of NanoBUP Capsules relative to Suboxone
时间窗: 72 hours
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
A phase 1b study to evaluate the pharmacokinetics and safety of CLE-600 in patients with Parkinson*s diseaseParkinson's diseaseNL-OMON53497Clexio Biosciences Ltd20
进行中（未招募）
不适用
A study in healthy volunteers to understand the distribution of OX27 in the bodyHealthy volunteers (Treament of breakthrough pain)EUCTR2011-001325-25-SEOrexo AB
已完成
1 期
Study to Assess Pharmacokinetics, Pharmacodynamics and Safety of Tiprogrel in Healthy SubjectsIschemic StrokeAcute Coronary SyndromeNCT06584812Tianjin Institute of Pharmaceutical Research Co., Ltd14
已完成
1 期
Pharmacokinetic And Pharmacodynamic Study Of A Single-Dose Of PF-04950615 (RN316) In Combination With AtorvastatinHypercholesterolemiaDyslipidemiaNCT01163851Pfizer25
已完成
1 期
A Study of the Safety and How the Body Effects a Drug CNTO 136 in Healthy Male Japanese and Caucasian VolunteersHealthyNCT00844909Centocor, Inc.62